Moghavem Nuriel, Morrison Doug, Ratliff John K, Hernandez-Boussard Tina
Stanford School of Medicine, Stanford, California.
Departments of 2 Surgery and.
J Neurosurg. 2015 Jul;123(1):189-97. doi: 10.3171/2014.12.JNS14447. Epub 2015 Feb 6.
Postsurgical readmissions are common and vary by procedure. They are significant drivers of increased expenditures in the health care system. Reducing readmissions is a national priority that has summoned significant effort and resources. Before the impact of quality improvement efforts can be measured, baseline procedure-related 30-day all-cause readmission rates are needed. The objects of this study were to determine population-level, 30-day, all-cause readmission rates for cranial neurosurgery and identify factors associated with readmission.
The authors identified patient discharge records for cranial neurosurgery and their 30-day all-cause readmissions using the Agency for Healthcare Research and Quality (AHRQ) State Inpatient Databases for California, Florida, and New York. Patients were categorized into 4 groups representing procedure indication based on ICD-9-CM diagnosis codes. Logistic regression models were developed to identify patient characteristics associated with readmissions. The main outcome measure was unplanned inpatient admission within 30 days of discharge.
A total of 43,356 patients underwent cranial neurosurgery for neoplasm (44.23%), seizure (2.80%), vascular conditions (26.04%), and trauma (26.93%). Inpatient mortality was highest for vascular admissions (19.30%) and lowest for neoplasm admissions (1.87%; p < 0.001). Thirty-day readmissions were 17.27% for the neoplasm group, 13.89% for the seizure group, 23.89% for the vascular group, and 19.82% for the trauma group (p < 0.001). Significant predictors of 30-day readmission for neoplasm were Medicaid payer (OR 1.33, 95% CI 1.15-1.54) and fluid/electrolyte disorder (OR 1.44, 95% CI 1.29-1.62); for seizure, male sex (OR 1.74, 95% CI 1.17-2.60) and index admission through the emergency department (OR 2.22, 95% CI 1.45-3.43); for vascular, Medicare payer (OR 1.21, 95% CI 1.05-1.39) and renal failure (OR 1.52, 95% CI 1.29-1.80); and for trauma, congestive heart failure (OR 1.44, 95% CI 1.16-1.80) and coagulopathy (OR 1.51, 95% CI 1.25-1.84). Many readmissions had primary diagnoses identified by the AHRQ as potentially preventable.
The frequency of 30-day readmission rates for patients undergoing cranial neurosurgery varied by diagnosis between 14% and 24%. Important patient characteristics and comorbidities that were associated with an increased readmission risk were identified. Some hospital-level characteristics appeared to be associated with a decreased readmission risk. These baseline readmission rates can be used to inform future efforts in quality improvement and readmission reduction.
术后再入院情况很常见,且因手术类型而异。它们是医疗保健系统支出增加的重要驱动因素。减少再入院是一项国家优先事项,为此已投入了大量努力和资源。在衡量质量改进措施的影响之前,需要了解与手术相关的30天全因再入院率基线。本研究的目的是确定颅骨神经外科手术的人群水平30天全因再入院率,并确定与再入院相关的因素。
作者使用医疗保健研究与质量局(AHRQ)加利福尼亚州、佛罗里达州和纽约州的住院患者数据库,确定了颅骨神经外科手术患者的出院记录及其30天全因再入院情况。根据ICD-9-CM诊断代码,将患者分为4组,代表手术指征。建立逻辑回归模型以确定与再入院相关的患者特征。主要结局指标是出院后30天内的非计划住院。
共有43356例患者接受了颅骨神经外科手术,其中肿瘤手术(44.23%)、癫痫手术(2.80%)、血管疾病手术(26.04%)和创伤手术(26.93%)。血管疾病入院患者的住院死亡率最高(19.30%),肿瘤入院患者的住院死亡率最低(1.87%;p<0.001)。肿瘤组30天再入院率为17.27%,癫痫组为13.89%,血管组为23.89%,创伤组为19.82%(p<0.001)。肿瘤患者30天再入院的显著预测因素是医疗补助支付者(OR 1.33,95%CI 1.15-1.54)和液体/电解质紊乱(OR 1.44,95%CI 1.29-1.62);癫痫患者为男性(OR 1.74,95%CI 1.17-2.60)和通过急诊科首次入院(OR 2.22,95%CI 1.45-3.43);血管疾病患者为医疗保险支付者(OR 1.21,95%CI 1.05-1.39)和肾衰竭(OR 1.52,95%CI 1.29-1.80);创伤患者为充血性心力衰竭(OR 1.44,95%CI 1.16-1.80)和凝血功能障碍(OR 1.51,95%CI 1.25-1.84)。许多再入院患者的主要诊断被AHRQ确定为可能可预防的。
接受颅骨神经外科手术患者的30天再入院率因诊断而异,在14%至24%之间。确定了与再入院风险增加相关的重要患者特征和合并症。一些医院层面的特征似乎与再入院风险降低相关。这些基线再入院率可用于为未来的质量改进和减少再入院工作提供参考。